Vulvovaginal candidiasis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vulvovaginal candidiasis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Metronidazole, Neomycin Sulfate, and Nystatin for Women with Bacterial Vaginosis and Yeast Infections https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-metronidazole-neomycin-sulfate-and-nystatin-for-women-with-bacterial-vaginosis-and-yeast-infections/ Wed, 29 Apr 2026 14:57:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-metronidazole-neomycin-sulfate-and-nystatin-for-women-with-bacterial-vaginosis-and-yeast-infections/ This clinical trial is focused on studying the treatment of two common vaginal infections: bacterial vaginosis and vulvovaginal candidiasis. Bacterial vaginosis is an infection caused by an imbalance of bacteria in the vagina, while vulvovaginal candidiasis is a yeast infection. The study will compare the effectiveness and safety of two treatments: Metronidazole/Neomycin Sulfate/Nystatin pessaries and Tergynan vaginal tablets. Both treatments are designed to be used vaginally to help clear these infections.

The purpose of the study is to determine if the Metronidazole/Neomycin Sulfate/Nystatin pessaries are as effective and safe as the Tergynan vaginal tablets in treating these infections. Participants in the study will use one of these treatments for a period of 10 days. During this time, researchers will monitor the participants to see how well the infections respond to the treatment and to check for any side effects. The study aims to provide a better understanding of which treatment option is more effective in achieving a cure for these infections.

Participants will be asked to follow specific guidelines during the study, such as avoiding certain activities and products that could interfere with the treatment. The study will help determine the best treatment option for women suffering from bacterial vaginosis and vulvovaginal candidiasis, potentially leading to improved care and outcomes for these common conditions.

]]> Study on the Effectiveness of Albaconazole and Fluconazole for Treating Acute Vaginal Yeast Infections in Women https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-albaconazole-and-fluconazole-for-treating-acute-vaginal-yeast-infections-in-women/ Wed, 29 Apr 2026 14:26:54 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-albaconazole-and-fluconazole-for-treating-acute-vaginal-yeast-infections-in-women/ This clinical trial is focused on studying the treatment of acute vulvovaginal candidiasis, a common yeast infection that affects the vaginal area, causing symptoms like itching, burning, and irritation. The study will compare the effectiveness and safety of a new medication called Albaconazole (also known by its code name UR-9825) with another medication, Fluconazole, and a placebo. Both Albaconazole and Fluconazole are taken as hard capsules by mouth.

The purpose of the study is to determine how well different single doses of Albaconazole work in treating the infection compared to a placebo. Participants will be randomly assigned to receive either Albaconazole, Fluconazole, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps ensure that the results are not biased.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The main goal is to see if the symptoms of the infection are completely resolved by the end of the study. The trial will help researchers understand the best dose of Albaconazole for treating acute vulvovaginal candidiasis and compare its effectiveness to Fluconazole and a placebo.

]]>